Kala Pharmaceuticals, Inc. (KALA)

One fine morning - boom - buyout @$3 minimum

Gl!

Kind attn: CEO and the Board of Directors 

As a shareholder who lost substantial amount of money I’m surprised and still don’t understand  why the Company should spend  $100 mln + in the next 2 years only going to be either failure or sold at a huge loss like it’s predecessor Drugs.

Kala is Done shareholders lost over $700 mln in this failed experiment. 

There is no point in any future development as we are not running a Government funded or non profit enterprise  since there is no way we could achieve viability in our experiments. Past work on both the Drugs proves that this Company is DESTINED TO FAIL FINANCIALLY.

Company should Pay up the Remaining Debt and make it debt free and put the Drug which is on development for Sale. If there is no buyer it is very clear that the Street don’t see your idea a viable one, period. This is Common sense.

Board should spin off the Royalty interest into a Trust along with the NOL and engage a reputed Trustee with definitive cost and expense information of running the Trust for the benefit of Shareholders.

Alcon should be allowed to takeover the manufacturing plant and close out the shop by paying off the remaining cash to shareholders.

As an experiment Kala is a Disaster and a total failure and it is time to call it off.

Thanking you,

Added another 25 k shares - I own 100 k now. I’m convinced - on my own- given the orphan drug - potential of KPI012 anyone will buy these guys out.

I’m not expecting much but definitely $3 is possible.

It is less than an option price.

Gl!

So their lender is Oxford Finance LLC a private equity lender. The interest rate is LIBOR plus 8...not a friendly FDIC Bank lender rate. The loans are collateralized by ALL company assets. This would include all IP...everything.

They're not loan sharks...no thumbs will be broken when payment is delayed. They're at least one step above that but it's no surprise to me that the valuation is net of the debt valuing their assets at ZERO. After being roasted by this group there are no more Wall St Believers. Contemplating taking the hit and moving on myself as I cannot stand listening to these people and this MED guy who sounds like Mr Haney from Green Acres. lol

Kind Attn: Mr. Mark Iwicki, Chairman & Board of Directors

Dear Sirs,

As a shareholder myself and as a CEO  yourself, we should all think whether we are running a commercial for profit enterprise or a charitable non profit organization.

The company’s 2 commercial products were sold for $60 mln when the development costs were almost $700 mln. With the market being as is it is, time for the company to sell itself or wind down rather than spending money like a Drunken Sailor with the development of Unmarketable and unviable products. We are not an incubator or a company funded by Government grants or from any charity organization. This is a For Profit enterprise.

At time as a CEO you need to look around and see what is left here instead of hemorrhaging further and further when there is absolutely no value left. Even if you develop any drug you can’t sell it profitably and it is time to call it quits.

Hope better Common sense prevails at the top management level instead of destroying valuation further.

Company direction and stock value

Kind Attn: Mr. Mark Iwicki, Chairman & Board of Directors

Dear Sir,

After pronouncement of Completion of Sale of 2 Approved assets and your future plans the Market has spoken and gave a THUMBS DOWN and it didn't like your grandiose plans for the Company.

The company promised Heaven and Earth for both of its approved Drugs and spent nearly $700 MLN (Seven Hundred Million Dollars) in full and years of work only to be sold for a Paltry $60 mln with a very uncertain future Royalty Payments.

I think the Company SHOULD WIND DOWN and SELL ITS REMAINING ASSET to some bigger pharma if there is a willing Buyer OR ABANDON the DEVELOPMENT if NONE is available which might prove the rest of the Industry don't believe and share in the Company's Management's vision and prospects  for this DRUG and  the Company should wind down, distribute the Remaining Cash to shareholders after Payment of remaining Debt.

The Future Alcon Royalty Payables should be SPUN OFF along with the NOLs and assign to a Professional Management company so that the Shareholders can receive some benefit if and when Alcon achieves the milestones.

As a Long term shareholder it is time for the Company to Cut its losses and save whatever is left since this experiment failed miserably and costed the shareholders lots of their wealth.

Thanking you,
Yours truly,

Having struck here will hold till a final outcome. Either Zero or Hero.

This stem cell research if successful will be a jackpot. Someone should buy them
Out for a decent value given the orphan drug designation

Gl!